Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 9/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 0.71 |
| ▸ | MLNR | O43193 | 1/20 | 0.71 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | DRD2 | P14416 | 1/20 | 0.71 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | HTR2C | P28335 | 1/20 | 0.71 |
| ▸ | MC4R | P32245 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-Norduloxetine SCHEMBL2634027 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| R-Norduloxetine SCHEMBL3268853 | 0.99 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| R-Norduloxetine SCHEMBL3890591 | 0.93 | SLC6A2 (0.86) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL17280843 | 0.91 | SLC6A2 (0.83) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL27847199 | 0.90 | SLC6A2 (0.82) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL27847200 | 0.90 | SLC6A2 (0.82) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL12212180 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL4563199 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL20292590 | 0.85 | CACNA2D1 (0.74) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| Methylamine SCHEMBL27678263 | 0.84 | SLC6A2 (0.72) | SLC6A2SLC6A4SLC6A3HTR1AMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008081476-A2 | PROCESS FOR PREPARING DULOXETINE HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2008-07-10 | — | — | WO | claimed |
| EP-2558455-B1 | SYNTHESIS OF DULOXETINE AND/OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA D D NOVO MESTO (SI) | 2017-08-09 | — | — | EP | disclosed |
| US-7928250-B2 | Reduction; condensation | SYNTHON BV (NL) | 2011-04-19 | — | — | US | disclosed |
| US-20080171887-A1 | Process for making duloxetine and related compounds | SYNTHON BV (NL) | 2008-07-17 | — | — | US | disclosed |
| WO-2008081476-A2 | PROCESS FOR PREPARING DULOXETINE HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081476-A2 | PROCESS FOR PREPARING DULOXETINE HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171887-A1 | Process for making duloxetine and related compounds | UGT1A10, UGT1A4, UGT1A6 | SLC6A2 33/4885SLC6A4 16/4885SLC6A3 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.